OSSIO is an orthopedic medical device company with the slogan "Only Nature Remains." Founded in Israel in 2014, the company aims to revolutionize the orthopedic experience for physicians, patients, and payors. Their mission is to disrupt the $10B+ orthopedic fixation market by replacing metal implants with an intelligent bone regeneration technology. Ossio's OSSIOfiber™ represents a breakthrough material platform for orthopedic and podiatric surgeons, offering a more biologically friendly way to restore mobility with nothing permanent left behind. The products provide the necessary mechanical strength for easy insertion and secure fixation while enabling the body to regrow bone, completely incorporating and replacing the implant without adverse inflammation and weakness often seen in "bio-resorbables." The company is headquartered in the United States, and their latest investment was a $38.50M Series C investment from MVM Partners on 17 October 2022.
No recent news or press coverage available for OSSIO.